Verrica Pharmaceuticals Inc   (VRCA)
Other Ticker:  
Price: $6.8500 $0.06 0.884%
Day's High: $6.95 Week Perf: -2.97 %
Day's Low: $ 6.72 30 Day Perf: 38.1 %
Volume (M): 86 52 Wk High: $ 7.76
Volume (M$): $ 590 52 Wk Avg: $5.23
Open: $6.78 52 Wk Low: $2.86

 Market Capitalization (Millions $) 316
 Shares Outstanding (Millions) 46
 Employees -
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -48
 Cash Flow (TTM) (Millions $) 52
 Capital Exp. (TTM) (Millions $) 0

Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc is a pharmaceutical company that specializes in developing and commercializing medical products for dermatology. They focus on providing innovative solutions for common skin conditions, such as viral infections like molluscum contagiosum and other dermatological ailments. Their products are designed to be safe, effective, and easy to use, offering patients convenient treatment options. Verrica Pharmaceuticals aims to improve the quality of life for individuals suffering from these conditions through their research, development, and commercialization efforts.

   Company Address: 44 West Gay Street West Chester 19380 PA
   Company Phone Number: 453-3300   Stock Exchange / Ticker: NASDAQ VRCA


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Licensing Agreement

Verrica Pharmaceuticals Receives FDA's New Chemical Entity Status for YCANTH

Published Tue, Mar 26 2024 11:30 AM UTC

Verrica Pharmaceuticals, a renowned pharmaceutical company, has recently announced that its product YCANTH has received the prestigious New Chemical Entity (NCE) status from the U.S. Food and Drug Administration (FDA). This regulatory milestone grants Verrica a minimum of five years of market exclusivity, paving the way for potential commercial success and furthering their m...

Product Service News

Verrica Pharmaceuticals Secures Permanent J-Code for First FDA-Approved Molluscum Contagiosum Treatment

Published Mon, Jan 29 2024 12:30 PM UTC

Verrica Pharmaceuticals, a leading dermatology therapeutics company, has recently received a significant milestone in its quest to provide medical interventions for skin diseases. The Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code (J7354) for Verrica's groundbreaking medication, YCANTH. This marks a crucial step forward in treating molluscum con...

Clinical Study

Revolutionizing BCC Treatment: VP-315, a Potential Game-Changer in Oncolytic Peptide-Based Immunotherapy

Published Fri, Jan 5 2024 12:30 PM UTC

Basal cell carcinoma (BCC) is the most common type of skin cancer, affecting millions of individuals each year in the United States alone. Despite its prevalence, there remains a significant unmet need for effective treatment options that tackle this malignancy. In this article, we explore the potential of VP-315, a first-in-class oncolytic peptide-based immunotherapy, as a ...

Management Announcement

Verrica Pharmaceuticals Advances Clinical Development of YCANTH for Common Warts Following Positive FDA Meeting

Published Thu, Jan 4 2024 12:30 PM UTC

In a recent announcement, Verrica Pharmaceuticals Inc. revealed that it has received the minutes from its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the clinical development of YCANTH for the treatment of common warts. This meeting was held on November 6, 2023, with the aim of discussing the Phase 3 clinical development plan for th...


Verrica Pharmaceuticals Teams Up with Walgreens to Revolutionize Distribution of YCANTH Therapy

Published Wed, Jan 3 2024 12:30 PM UTC

Verrica Pharmaceuticals Expands Distribution Network with Walgreens Specialty Pharmacy PartnershipWEST CHESTER, Pa., Jan. 03, 2024 - Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leading dermatology therapeutics company focused on developing medications for skin diseases requiring medical interventions, announced its latest endeavor to widen its distribution network. The co...


Verrica Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com